A Year Of Surprises Shakes Up Off-Patent Industry
Sandoz, Mylan And Teva Switch Places At The Top
After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.
You may also be interested in...
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.
Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.